Agios Pharmaceuticals AGIO Interest Income (Expense), Nonoperating
Interest Income (Expense), Nonoperating at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's interest income (expense), nonoperating.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's interest income (expense), nonoperating?
- Agios Pharmaceuticals (AGIO) reported interest income (expense), nonoperating of $10.8M in Q1 2026.
- How has Agios Pharmaceuticals's interest income (expense), nonoperating changed year-over-year?
- Agios Pharmaceuticals's interest income (expense), nonoperating decreased by 32.9% year-over-year, from $16.09M to $10.8M.
- What is the long-term trend for Agios Pharmaceuticals's interest income (expense), nonoperating?
- Over 3 years (2021 to 2025), Agios Pharmaceuticals's interest income (expense), nonoperating has grown at a 307.0% compound annual growth rate (CAGR), from $836K to $56.38M.